Hydrolysable-tannin–rich fraction from terminalia chebula and standardized solid compositions

IN607526BActive Publication Date: 2026-10-28RIMA JOSEPH
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
IN202541100573
Authority / Receiving Office
IN · IN
Patent Type
Patents
Current Assignee / Owner
Filing Date
2025-10-17
Publication Date
2026-10-28
Estimated Expiration
2045-10-17

AI Technical Summary

Technical Problem

Existing Terminalia chebula extracts lack reproducible identity and stability due to broad compositional ranges and variable extraction processes, leading to inconsistent solid-form performance and batch variability.

Method used

A defined hydrolysable-tannin-rich fraction (HTF) from Terminalia chebula, characterized by marker-based analytical specifications and a parameter-critical extraction–adsorption–elution sequence, formulated into standardized solid compositions with excipient systems to ensure identity, purity, and content uniformity.

Benefits of technology

The HTF achieves reproducible and stable hydrolysable-tannin compositions with defined dissolution profiles, minimizing batch variability and ensuring consistent performance across lots.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

TITLE: HYDROLYSABLE-TANNIN–RICH FRACTION FROM TERMINALIA CHEBULA AND STANDARDIZED SOLID COMPOSITIONS ABSTRACT Disclosed are compositions titled “HYDROLYSABLE-TANNIN–RICH FRACTION FROM TERMINALIA CHEBULA AND STANDARDIZED SOLID COMPOSITIONS.” A human-made hydrolysable-tannin–rich fraction (HTF) is analytically defined by (i) total hydrolysable tannins 85–98% w / w, (ii) a marker panel comprising chebulagic acid, chebulinic acid, corilagin, and tellimagrandin I within preset ranges, (iii) free ellagic acid 1.0–5.0% w / w, and (iv) orthogonal identity criteria including HPLC retention-time windows and an HR-LCMS base-peak chromatographic fingerprint. Standardized solid compositions comprise the HTF and ingestible excipients in unit solid forms meeting content-uniformity and dissolution specifications; optional protective or enteric coatings control acid-phase release and post-gastric delivery. Packaging with defined moisture-barrier performance maintains stability. The disclosure provides acceptance criteria linking raw-material identity, in-process controls, and finished-product testing to ensure lot-to-lot reproducibility, thereby distinguishing the defined fraction and standardized solids from variably characterized botanical extracts. Quantitative marker contents are established by validated chromatographic assay, while an HR-LCMS base-peak chromatogram provides an orthogonal identity fingerprint FIG.1 is selected. 16 Claims, 5 Drawing Sheets DATE: 16-October-2025 Keerthi J S PLACE: BANGALORE COUNSEL FOR THE APPLICANT-IN / PA-1729
Need to check novelty before this filing date? Find Prior Art

Description

A) TECHNICAL FIELD

[0001] The present invention relates to compositions derived frombotanical sources and, more particularly, to defined hydrolysable-tannin–richfractions obtained from Terminalia chebula and standardized solidcompositions comprising such fractions with marker-based analyticalspecifications. The invention is especially applicable to polyphenolicfractionation and solid-form standardization, including processes and qualitycontrolframeworks that enable reproducible identity, purity, contentuniformity, and stability in unit solid forms (e.g., coated tablets or capsules)produced via controlled extraction, purification, and formulation.B) BACKGROUND OF THE INVENTION

[0002] Polyphenolic extracts from botanical sources are widely reportedto contain complex mixtures of hydrolysable tannins (e.g., ellagitannins andgallotannins) with variable composition, stability, and bio-performance due todifferences in plant part, harvest conditions, and extraction methodology.Conventional disclosures describe Terminalia chebula fruit as a tannin-richsource containing chebulinic acid, chebulagic acid, corilagin, and relatedmetabolites; however, such disclosures typically emphasize broadcompositional descriptions rather than a narrowly characterized, fractiondefinedidentity suitable for reproducible solid-form standardization (Patentdocument number: WO2013155175A1 tilted “Terminalia chebulacompositions and method of extracting same”).

[0003] Prior-art compositions specifically referencing Terminaliachebula often disclose enriched tannoids within wide ranges (e.g., chebulagicacid 8–25% and chebulinic acid 15–30%, together with other low-molecularweighthydrolysable tannoids), and provide generic extraction workflows.While these disclosures establish that T. chebula yields tannin-rich extracts,they do not mandate an analytical fingerprint and acceptance criteria thatensure lot-to-lot identity, purity, and content uniformity in standardized solidcompositions.

[0004] Separately, process-focused art on polyphenol fractionationteaches adsorption or chromatographic separations to concentrate phenolicsfrom diverse matrices (e.g., grape extracts or plant tannins) using nonoxidizingmedia and resins. Such teachings demonstrate feasibility ofpolyphenol enrichment but remain agnostic to Terminalia chebula–specificconstraints (pH windows, solvent polarity progression, resin type / sequence)necessary to preserve ellagitannin / gallotannin integrity and to yield a definedhydrolysable-tannin fraction with marker-bound specifications fordownstream solid-form standardization (Patent document number:US6238673B1and titled: “Method of producing high flavonol contentpolyphenol compositions”.

[0005] Additional phytochemical literature characterizes the structuraldiversity and lability of hydrolysable tannins in T. chebula, noting numerousellagitannins and related artifacts. Such complexity heightens the risk thatsmall variations in extraction pH, time, and solvent order can degradefingerprint consistency, underscoring the need for a manufacturing approachthat outputs a fraction whose identity is constrained by analytical markersrather than by plant origin alone.

[0006] Other standardization-focused herbal compositions include T.chebula as one component of multi-herbal formulations, again providingnominal marker ranges. However, these documents do not disclose a singlesourcehydrolysable-tannin–rich fraction from T. chebula that is (i) defined bya multi-marker analytical fingerprint, (ii) produced under parameter-criticalextraction and resin-elution conditions tailored to hydrolysable tannins, and(iii) formulated into standardized solid compositions with release and stabilityspecifications.

[0007] In parallel, there exists a recognized demand for non-hormonalmale fertility control modalities, evidenced by clinical and preclinicalreporting on hormone-based gels and emerging non-hormonal agents. Suchreporting highlights systemic side effects, compliance considerations, andtranslational gaps, motivating exploration of non-hormonal, orally deliverablecompositions with favorable safety signals. Prior patent literature on malecontraception predominantly addresses hormonal approaches or distinct smallmoleculetargets, not standardized polyphenolic fractions from T. chebula withdefined analytical identity.

[0008] Against this backdrop, existing T. chebula extracts present at leastthree limitations: (i) compositional ambiguity—extracts are described by broadranges without mandatory marker–to–marker ratio controls; (ii) manufacturingvariability—extraction conditions (pH, time, solvent sequence) and resinchoices are not shown to be critical to preserving a stable hydrolysable-tanninprofile; and (iii) dosage-form reproducibility—solid compositions lack definedrelease, stability, and acceptance criteria tied to a specified fraction identityrather than to bulk extract labels.

[0009] The art thus does not provide a hydrolysable-tannin–rich fractionfrom T. chebula that is both (a) analytically characterized by pre-set markerwindows (e.g., defined percentages or ranges for chebulagic acid, chebulinicacid, and specified related tannins, together with optionally constrained freeellagic acid) and (b) manufactured via a parameterized extraction–partition–adsorption–elution sequence demonstrated to be critical to achieving saidfingerprint reproducibly across lots intended for standardized solidcompositions.

[0010] Furthermore, generic polyphenol concentration methods do notarticulate the coupling between process parameters (acidified hydro-alcoholicextraction within a narrow pH band; bounded extraction time; sequentialnonpolar partitioning; hydrophobic resin adsorption; controlled water washand polar-solvent elution) and measurable lot-release criteria that define theidentity of a T. chebula hydrolysable-tannin fraction. Absent such coupling,process drift or minor plant-to-plant variability can yield materially differenttannin distributions, compromising reproducibility in unit solid forms.

[0011] There is therefore a need for a T. chebula–derived, hydrolysabletannin–rich fraction whose identity is expressed not by plant taxonomy orgeneric “extract” nomenclature, but by marker-based analytical specifications(e.g., HPLC / HR-LCMS fingerprints and marker percentage ranges) that areobtained only when defined manufacturing parameters are observed, andwhich identity is preserved through conversion into standardized solidcompositions with content-uniformity and stability acceptance criteria.

[0012] The present invention addresses this need by providing: (i) adefined hydrolysable-tannin fraction from Terminalia chebula characterizedby marker-bound specifications that constrain ellagitannin and gallotannindistributions; and (ii) standardized solid compositions comprising said fractionin unit solid forms (e.g., coated tablets or capsules) with excipient systems andprocess controls that ensure identity, purity, and content uniformity at releaseand over shelf life. In contrast with disclosures that merely enrich tannins, theclaimed fraction is analytically delimited and manufacture-linked toparameter-critical steps, thereby producing a reproducible composition ofmatter rather than a loosely specified extract.

[0013] By anchoring identity to quantitative marker windows and byprescribing an extraction–adsorption–elution sequence under defined pH, time,and solvent conditions, the invention improves over resin-based polyphenolconcentration art that does not teach preservation of hydrolysable-tanninintegrity specific to T. chebula, nor tie process parameters to acceptancecriteria for solid-form standardization. The result is a fraction suitable forscale-up with reduced batch-to-batch variability relative to the polyphenolrecovery routes disclosed for unrelated matrices.

[0014] In preferred embodiments, the standardized solid compositionsincorporate enteric or protective coatings and excipient systems selected tostabilize hydrolysable tannins against premature hydrolysis and oxidation,enabling defined dissolution profiles and minimizing intra-batch variability.Prior multi-herb standardizations citing T. chebula do not disclose suchcomposition-level controls tied to a single-source hydrolysable-tannin fractionwith marker-linked identity.

[0015] Collectively, the present invention thus overcomes theshortcomings of (i) broad-range extract descriptions lacking enforceableidentity, (ii) process-general polyphenol enrichments lacking T. chebula–specific preservation constraints, and (iii) non-standardized solid forms lackingrelease / stability criteria. The invention supplies a defined composition ofmatter and standardized solid compositions whose reproducibility isdemonstrated through marker-based specifications and parameter-criticalmanufacture, thereby meeting an unmet need for reliable, analyticallycontrolled hydrolysable-tannin compositions derived from Terminalia chebula.

[0016] The above-mentioned shortcomings, disadvantages and problemsare addressed herein, which will be understood by reading the followingspecification.C) OBJECTS OF THE INVENTION

[0017] The primary object of the present invention is to provide a definedhydrolysable-tannin–rich fraction obtained from Terminalia chebula,characterized by marker-based analytical specifications that establishreproducible identity and purity, according to an embodiment of the presentinvention.

[0018] The other object of the present invention is to providestandardized solid compositions comprising the defined fraction in unit solidforms with predetermined content-uniformity and release acceptance criteriasuitable for manufacturing scale-up, according to the embodiment of thepresent invention.

[0019] Another object of the present invention is to establishcompositional boundaries expressed by quantitative marker ranges (includingspecified ellagitannin / gallotannin markers and permitted limits for relatedsubstances) and corresponding chromatographic fingerprints that enable lotto-lot conformity, according to the embodiment of the present invention.

[0020] Another object of the present invention is to enhance stability ofthe defined fraction within solid compositions through excipient selection andoptional protective or enteric coatings, thereby mitigating hydrolysis andoxidation and extending shelf-life under standard storage conditions, accordingto the embodiment of the present invention.

[0021] Another object of the present invention is to provide a quality20control framework linking in-process controls and finished-productspecifications—comprising identity, assay, impurities, dissolution, andstability parameters—to ensure consistent performance of the standardizedsolid compositions across manufacturing batches, according to theembodiment of the present invention.

[0022] These and other objects and advantages of the present inventionwill become readily apparent from the following detailed description taken inconjunction with the accompanying drawings.D) SUMMARY OF THE INVENTION

[0023] The embodiments of the present invention disclose a definedhydrolysable-tannin–rich fraction obtained from Terminalia chebula andstandardized solid compositions comprising said fraction, wherein identity isconstrained by marker-based analytical specifications and release acceptancecriteria configured to ensure reproducible composition and performance.

[0024] According to the embodiment, the defined fraction comprises acontrolled distribution of ellagitannins and gallotannins, the distribution beingspecified by quantitative ranges for a plurality of marker compounds and by achromatographic fingerprint, thereby distinguishing the fraction from genericplant extracts and enabling lot-to-lot conformity.

[0025] According to the embodiment, the standardized solidcompositions include unit solid forms comprising the defined fraction and oneor more pharmaceutically acceptable excipients selected to provide contentuniformity and stability; in preferred embodiments, optional protective orenteric coatings are applied to mitigate hydrolysis and oxidative degradationduring storage and transit through the gastrointestinal environment.

[0026] In one embodiment, the disclosure provides analytical acceptancecriteria including, without limitation, (i) identity confirmation by HPLC and / orHR-LCMS retention-time and ion-ratio windows, (ii) assay limits for totalhydrolysable tannins and individual marker compounds, and (iii) permittedlevels for related substances and residual solvents, whereby the compositionsmeet predetermined specifications at release and over shelf life.

[0027] In another embodiment, the disclosure provides dissolutionacceptance criteria for the unit solid forms, the criteria defining a releaseprofile consistent with preservation of the hydrolysable-tannin distribution; theprofile is maintained by excipient selection and coating parameters that controlingress of moisture and pH-triggered disintegration.

[0028] In a further embodiment, the disclosure contemplatesmanufacturing controls for blending, granulation, compression, and coatingoperations that are configured to maintain the integrity of the defined fraction,including temperature and humidity set-points, exposure time limits, and inprocesssampling plans tied to the marker-based identity of the fraction.

[0029] In certain embodiments, the standardized solid compositions arepackaged with desiccant systems and barrier materials selected to limit watervapor transmission within predefined limits, thereby maintaining stability ofthe hydrolysable-tannin distribution under ICH-aligned storage conditions.

[0030] In another embodiment, the disclosure contemplates specificationdocuments and batch records that link raw-material acceptance (fractionidentity and assay), in-process controls (blend uniformity and loss-on-drying),and finished-product testing (assay, related substances, dissolution, andstability), thereby enabling reproducible manufacture at commercial scale.

[0031] In embodiments, the defined fraction is further characterized byratio constraints among select marker compounds, the ratio constraints servingas secondary identifiers that detect compositional drift arising from sourcevariability or process deviations, thus ensuring that only lots meeting bothabsolute and relative marker specifications are released to formulation.

[0032] In yet another embodiment, the standardized solid compositionscomprise unit doses selected within a predetermined mass range of the definedfraction and exhibit content uniformity meeting compendial criteria, theuniformity being verified by validated analytical methods aligned to the markerpanel specified for the fraction.

[0033] In embodiments, the disclosure contemplates kits comprising thestandardized solid compositions and accompanying quality documentationidentifying marker specifications, analytical methods, and storage conditions,the kit components being configured to preserve and verify the defined identityof the hydrolysable-tannin fraction throughout distribution.

[0034] Collectively, the embodiments provide a composition-centricframework in which a hydrolysable-tannin–rich fraction from Terminaliachebula is defined by quantitative analytical specifications and formulated intostandardized solid compositions under linked manufacturing and qualitycontrolparameters, thereby delivering reproducible identity, purity, contentuniformity, and stability across production lots.

[0035] These and other aspects of the embodiments herein will be betterappreciated and understood when considered in conjunction with the followingdescription and the accompanying drawings. It should be understood,however, that the following descriptions, while indicating preferredembodiments and numerous specific details thereof, are given by way ofillustration and not of limitation. Many changes and modifications may bemade within the scope of the embodiments herein without departing from thespirit thereof, and the embodiments herein include all such modifications.E) BRIEF DESCRIPTION OF THE DRAWINGS

[0036] The other objects, features and advantages will occur to thoseskilled in the art from the following description of the preferred embodimentand the accompanying drawings in which:

[0037] FIG. 1. Illustrates the base peak chromatogram (HR-LCMS,negative mode) of the hydrolysable-tannin–rich fraction from Terminaliachebula, depicting marker distribution and serving as an identity confirmationprofile, according to an embodiment of the present invention.

[0038] FIG. 2. Illustrates the HPLC chromatogram of the hydrolysabletannin–rich fraction showing the retention-time window for ellagic acidemployed for routine identification and assay, according to an embodiment ofthe present invention.

[0039] FIG. 3. Illustrates relative gene-expression bar plots for AR,TMPRSS2, and SRD5A2 in testes, ventral prostate, and seminal vesicledemonstrating composition-linked modulation, according to an embodiment ofthe present invention.

[0040] FIG. 4. Illustrates representative liver and kidney histologicalmicrographs (100× / 200×) evidencing preserved tissue architecture in treatedanimals and supporting tolerability of the standardized compositions,according to an embodiment of the present invention.

[0041] FIG. 5. Illustrates the calibration curve of ellagic acid generatedby HPLC analysis for quantitative assay validation of a marker compoundwithin the fraction, according to an embodiment of the present invention

[0042] Although specific features of the present invention are shown insome drawings and not in others. This is done for convenience only as eachfeature may be combined with any or all of the other features in accordancewith the present invention.F) DETAILED DESCRIPTION OF THE INVENTION

[0043] In the following detailed description, reference is made to theaccompanying drawings that form a part hereof, and in which the specificembodiments that may be practiced is shown by way of illustration. Theseembodiments are described in sufficient detail to enable those skilled in the artto practice the embodiments and it is to be understood that the logical,mechanical and other changes may be made without departing from the scopeof the embodiments. The following detailed description is therefore not to betaken in a limiting sense.

[0044] The present disclosure arises from recognition that botanicalextracts labeled by plant source and part, without binding analytical identity,exhibit unacceptable variability in polyphenolic composition, stability, andsolid-form performance. Conventional Terminalia chebula preparations aretypically described as “extracts” or “enriched tannoids” with broad, nonenforcedranges for constituents, thereby failing to guarantee lot-to-lotreproducibility in downstream solid compositions. Such breadth in identityincreases the likelihood of compositional drift, oxidative degradation, andinconsistent release profiles in finished dosage forms.

[0045] The drawbacks of existing preparations include, withoutlimitation: (i) reliance on taxonomic identity rather than a constrainedanalytical fingerprint; (ii) absence of ratio-based specifications among keyellagitannin and gallotannin markers; (iii) insufficient coupling betweensource / process parameters and finished-product acceptance criteria; and (iv)lack of standardized solid composition frameworks that preserve hydrolysabletannin integrity over shelf life. As a consequence, prior materials labeled as T.chebula extract may be unsuitable for reproducible manufacture at scale.

[0046] The present invention provides a solution in the form of a definedhydrolysable-tannin–rich fraction (hereinafter “HTF”) from Terminaliachebula and standardized solid compositions comprising the HTF, wherein theHTF is characterized by a set of quantitative marker specifications and anaccompanying chromatographic fingerprint. The analytical identity isexpressed both by absolute content windows for selected markers and by ratioconstraints among those markers, thereby limiting acceptable compositionalvariance.

[0047] In embodiments, the HTF comprises a controlled distribution ofellagitannins and gallotannins selected from chebulagic-type and chebulinictypespecies together with structurally related polyphenolic constituents. TheHTF is defined by total hydrolysable tannins within a predetermined range(e.g., about 85% to about 98% by weight of the dry fraction), optionally withfree ellagic acid constrained within a narrower window (e.g., about 1.0% toabout 5.0% by weight), and with remaining mass comprised primarily ofrelated hydrolysable tannin congeners and residual moisture.

[0048] In embodiments, the HTF is further specified by absolute contentranges for a plurality of marker compounds, the markers being selected asrepresentative species of the hydrolysable-tannin distribution. Withoutlimitation, the marker panel may include chebulagic-type and chebulinic-typerepresentatives, corilagin-type representatives, and additional ellagitannincongeners, each constrained to a defined minimum and maximum weightpercentage based on validated chromatographic method

[0049] In embodiments, the identity of the HTF is additionally delimitedby ratio constraints among marker pairs or triplets (e.g., Marker A:Marker Band Marker A+Marker C:Marker D), wherein the specified ratios fall withinpredetermined intervals. The ratio constraints function as secondarydiscriminators that detect compositional drift not captured by absolute limitsalone, thus strengthening identity control.

[0050] The standardized solid compositions disclosed herein comprisethe HTF and one or more ingestible excipients conforming to compendial orinternally validated standards, the excipients being selected to provideprocessability, content uniformity, mechanical strength, and chemical stabilityunder defined environmental conditions. In embodiments, the unit solid formsinclude tablets, mini-tablets, capsules, or pelletized units contained within hardor soft shells.

[0051] In embodiments, protective or enteric coatings are applied to unitsolid forms to mitigate premature hydrolysis or oxidation of hydrolysabletannins. Suitable coating systems include, without limitation, methacrylic acidcopolymers, cellulose-based polymers, polyvinyl derivatives, and plasticizersystems selected to achieve disintegration at target pH and to limit moistureingress during storage. The coating selection and thickness are specified toachieve a defined dissolution profile for the HTF.

[0052] The disclosure includes acceptance criteria that collectivelydefine finished-product quality. In embodiments, acceptance criteria comprise:(i) identity confirmation by high-performance liquid chromatography (HPLC)and / or high-resolution liquid chromatography–mass spectrometry (HRLCMS),including retention-time (RT) windows and ion-ratio windows forselected markers; (ii) assay limits for total hydrolysable tannins and for eachmarker; (iii) permitted levels for related substances; (iv) content uniformitymeeting compendial or internal criteria; (v) dissolution specifications alignedto coating and excipient design; and (vi) stability specifications covering assay,related substances, moisture, and dissolution over time.

[0053] In embodiments, the chromatographic identity is establishedusing a validated HPLC method employing an appropriate reversed-phasecolumn and gradient elution, wherein marker peaks exhibit RT values within±ΔRT minutes of reference standards and comply with relative peak areatolerances. Where LC-MS is utilized, mass transitions or accurate-mass ionsfor markers are monitored, and ion-ratio tolerances are applied to confirmidentity against reference spectra.

[0054] In embodiments, the finished-product dissolution specification isexpressed as a percentage of HTF-associated marker release at discrete timepoints in defined media (e.g., pH 1.2, pH 4.5, and pH 6.8). The specificationensures that the protective or enteric coating enables transit through simulatedgastric conditions with controlled release thereafter, thereby preserving theintended hydrolysable-tannin distribution at the point of disintegration.

[0055] The manufacturing of standardized solid compositions isconfigured to maintain the integrity of the HTF. In embodiments, process stepsinclude controlled blending, wet or dry granulation (where applicable),compression or encapsulation, and coating. Each step is bounded by processparameters (e.g., temperature, humidity, residence time, and mechanical shear)selected to minimize polyphenolic degradation.

[0056] In embodiments, in-process controls (IPCs) include blenduniformity sampling employing validated sampling plans, loss-on-drying(LOD) monitoring to limit moisture-induced hydrolysis, and compaction forcewindows to avoid excessive localized heating. Coating operations incorporateinlet and product temperature bands, atomization parameters, and spray ratesset to avoid overwetting and to achieve target weight gain and film continuity.

[0057] In embodiments, the packaging system comprises barriercontainers, blisters, or sachets incorporating desiccant or humidity-regulatingcomponents, with water vapor transmission rate (WVTR) limits specified tomaintain moisture below a defined threshold throughout shelf life. Labelingincludes storage conditions consistent with stability data (e.g., “store below 25°C” or “store in a cool, dry place”), and tamper-evident features areincorporated where appropriate. The primary package is further configured tomaintain water activity (a_w) ≤ 0.40 at 25 °C / 60% RH inside the unit solidthroughout shelf life

[0058] The novelty of the present disclosure resides, inter alia, in thebinding of botanical identity to a quantitative marker specification set coupledwith ratio-based constraints, and in the explicit linkage of such identity to astandardized solid-form framework governed by dissolution and stabilityacceptance criteria. Unlike generic extracts, the HTF is a composition of matterdefined by measurable analytical attributes and release specifications, therebyenabling reproducible manufacture and quality assurance.

[0059] Definitions / Release Specifications. ‘HTF’ denotes ahydrolysable-tannin–rich fraction released only upon concurrent conformanceto: (i) total hydrolysable tannins 85–98% w / w (dry basis); (ii) marker windowscomprising chebulagic acid 5–20% w / w, chebulinic acid 10–30% w / w,corilagin 1–10% w / w, and tellimagrandin I 10–40% w / w; (iii) free ellagic acid1.0–5.0% w / w; and (iv) orthogonal identity comprising HPLC retention-timewindows with peak-purity acceptance and an HR-LCMS negative-mode basepeakchromatogram exhibiting acceptance-bounded marker-distribution andion-ratio profiles.

[0060] In embodiments, the HTF is prepared upstream via parameter20critical steps that, while not claimed herein as process claims, are disclosed toenable the skilled person to obtain material matching the analytical identity.Such steps include acidified hydro-alcoholic extraction within a defined pHband, time-bounded extraction to limit hydrolysis, sequential non-polarpartitioning to remove lipophilic impurities, adsorption on a non-ionichydrophobic resin, water washing to remove low-molecular-weightinterferents, and elution with a polar solvent to recover the HTF, followed byconcentration and drying.

[0061] In embodiments, the foregoing upstream steps are shown to becritical to achieving the HTF identity, as evidenced by comparative datademonstrating that deviations in pH, extraction time, or solvent / order selectionproduce material that fails one or more marker or ratio specifications. Thiscoupling of parameter windows to identity strengthens the definitionalboundaries of the HTF and distinguishes the disclosed composition from broad“extracts” in the art.

[0062] In embodiments, the HTF is formulated into standardized solidcompositions using excipient systems selected from diluents, binders,disintegrants, glidants, lubricants, and coating auxiliaries. Excipients arescreened for compatibility with hydrolysable tannins, with preference formaterials exhibiting low reactivity, low residual solvents, and minimalcatalytic activity toward hydrolysis or oxidation.

[0063] In embodiments, content uniformity is achieved by controllingparticle size distribution (PSD) of the HTF and excipients, employing blendingsequences that minimize segregation, and, where applicable, granulating underconditions that avoid excessive aqueous exposure. Acceptance criteria includeindividual unit assay within predefined percentage limits relative to target labelcontent.

[0064] In embodiments, related-substance limits are established based ondegradation pathways of hydrolysable tannins, including hydrolysis tophenolic acids and oxidative dimerization products. The specification setsqualified and unqualified thresholds in accordance with internal toxicologicalassessments and method capability, thereby ensuring that degradation productsremain within safe and predictable boundaries.

[0065] In embodiments, stability studies are conducted under acceleratedand long-term conditions aligned with recognized guidelines. Acceptancecriteria include retention of marker content within specified ranges,maintenance of ratio constraints, control of total related substances,preservation of dissolution behavior, and moisture content within limits.Failure of any parameter triggers investigation and corrective action per qualitysystems.

[0066] In embodiments, the disclosure further contemplates referencestandards and system suitability tests for the analytical methods. Referencestandards for markers are qualified for identity and purity, and systemsuitability includes tailing factor, theoretical plates, relative standard deviationof replicate injections, and resolution criteria to ensure method performanceprior to sample analysis.

[0067] In embodiments, the specification package for the HTF includes:(i) a certificate of analysis with marker and ratio results; (ii) moisture, ash, andresidual solvent data; (iii) microbial limits where applicable; and (iv) storagerecommendations. The specification package for the finished solidcomposition includes: (i) appearance; (ii) identification; (iii) assay; (iv) relatedsubstances; (v) content uniformity; (vi) dissolution; (vii) hardness or tensilestrength (for tablets); (viii) friability (where applicable); and (ix) stabilityassignment.

[0068] The invention thereby furnishes a composition-firststandardization strategy in which the HTF is not merely a plant extract but atightly bounded fraction with analytical identity and performance attributesreproducibly maintained through to the finished unit solid form. This approachaddresses the long-standing challenge of variability in botanical preparationsby imposing measurable, enforceable specifications at both raw and finishedstages.

[0069] In embodiments, kits are provided comprising one or more-unitsolid forms of the standardized composition and an accompanyingspecification sheet identifying marker content ranges, ratio constraints,dissolution criteria, and storage instructions. The kits may further includedesiccant-enabled secondary packaging to assist in maintaining environmentalcontrol after opening.

[0070] In embodiments, the disclosure contemplates scale-up andtechnology-transfer documentation, including critical quality attributes(CQAs) and critical process parameters (CPPs) mapping. CQAs includemarker content, ratio compliance, residual moisture, and dissolutionperformance; CPPs include blending time, granulation solvent exposure,compression force, and coating parameters. Control strategies are devised tokeep CPPs within proven acceptable ranges (PARs).

[0071] In embodiments, comparative examples demonstrate thatnominally similar materials labeled as T. chebula extract but produced outsidethe disclosed parameter windows fail one or more identity, ratio, dissolution,or stability specifications. These comparisons substantiate that the present HTFand standardized solid compositions achieve reproducibility and stabilityunattained by prior, broadly defined extracts.

[0072] In embodiments, optional antioxidants or chelators may beincluded at low levels to further mitigate oxidative pathways, provided suchadditions do not interfere with marker detection or alter ratio constraintsbeyond acceptable drift. Any such auxiliary component is included withinspecified ranges and justified by stability data.

[0073] In embodiments, moisture management is emphasized as a designprinciple. Process steps are sequenced to minimize aqueous exposure time,equipment and rooms are humidity-controlled, and packaging incorporatesmoisture barriers commensurate with the hygroscopicity profile of the HTF.Moisture-induced excursions observed during development informspecification tightening and process refinements.

[0074] The foregoing detailed description, while providing enablinginformation regarding identity, specification boundaries, solid-formstandardization, analytical confirmation, and stability assurance, is notlimiting. Variations in marker selection, ratio design, excipient choice, andcoating architecture that preserve the essential features—namely, ahydrolysable-tannin–rich fraction defined by quantitative analyticalspecifications and standardized solid compositions meeting linked acceptancecriteria—are within the scope of the present invention.

[0075] The disclosed material is a human-made, specification-boundfraction defined by quantitative marker ranges, ratio constraints, andorthogonal chromatographic identity; it is not a substance occurring in natureas such, not traditional knowledge, not a mere admixture, and does not claimany method of treatment

[0076] FIG. 1. Illustrates the base peak chromatogram (HR-LCMS,negative mode) of the hydrolysable-tannin–rich fraction from Terminaliachebula, depicting marker distribution and serving as an identity confirmationprofile, according to an embodiment of the present invention.

[0077] As shown, the FIG. 1 presents the base peak chromatogram(BPC) acquired by high-resolution liquid chromatography–mass spectrometry(HR-LCMS) in negative ionization mode for the hydrolysable-tannin–richfraction (HTF) obtained from Terminalia chebula. The BPC depicts the mostintense ion at each chromatographic time point and functions as an identityconfirmationprofile for the HTF, as listed under the “Supporting Documents”section of the specification.

[0078] The BPC profile evidences a multi-peak pattern consistent with adistribution of ellagitannin and gallotannin constituents. The relative peakintensities and elution order collectively define a fingerprint that distinguishesthe disclosed HTF from generic or partially characterized plant extracts,enabling batch release decisions based on predefined chromatographicacceptance criteria.

[0079] In embodiments, the BPC is generated using reversed-phase LCconditions suitable for polyphenolic analytes, with detection conducted byaccurate-mass MS in negative polarity to favor deprotonated molecular ions ofhydrolysable tannins. The resulting chromatographic trace provides retentiontime(RT) windows for targeted markers and establishes relative responsepatterns to be compared against qualified reference profiles.

[0080] The identity-confirmation utility of the BPC is reinforced bycompanion analytical records included in the application, namely a calibrationcurve for a representative marker (ellagic acid) and an HPLC chromatogramhighlighting the ellagic acid RT window in the HTF sample. Together, thesematerials support both qualitative identification (BPC pattern match) andquantitative assessment (marker assay linearity and RT confirmation).

[0081] In preferred embodiments, lot conformity is demonstrated when(i) the BPC exhibits all required marker peaks within specified RT tolerancesrelative to a reference standard run, and (ii) the relative peak-area ratios amongdesignated peaks fall within predefined intervals. The BPC thereby serves as aprimary identity test, while secondary tests (e.g., HPLC-UV RT confirmationfor ellagic acid) provide orthogonal corroboration.

[0082] “In certain embodiments, tellimagrandin I constitutes the singlemost abundant marker within the specified panel; in related embodiments,(tellimagrandin I):(chebulagic acid) is 1.2–6.0, and / or tellimagrandin I ≥ 20%w / w while (chebulagic acid + chebulinic acid) ≤ 45% w / w.

[0083] The BPC is further employed to monitor process consistency bydetecting compositional drift attributable to upstream parameter deviations(e.g., extraction pH, extraction duration, solvent partition order, or resinelutionconditions). Batches exhibiting missing peaks, RT shifts outsideacceptance windows, or aberrant relative responses are flagged forinvestigation and are not advanced to standardized solid-form manufacture.

[0084] In embodiments, the BPC fingerprint forms part of the certificateof analysis (CoA) for the HTF, with stored digital raw files (and processedtraces) enabling retrospective comparison during stability studies andtechnology transfer. The identity specification references the BPC alongsidequantitative marker ranges and ratio constraints to bind botanical origin tomeasurable analytical attributes.

[0085] The figure is configured to display annotated markerscorresponding to characteristic hydrolysable-tannin ions; annotations mayinclude tentative identifications based on accurate mass and fragmentationbehavior, cross-linked to the qualitative HPLC chromatogram and quantitativecalibration records. Such cross-referencing facilitates method validation,routine system-suitability checks, and inter-laboratory reproducibility.

[0086] The BPC-based identity framework disclosed herein is distinctfrom prior art that references T. chebula “extracts” without mandating achromatographic fingerprint; by contrast, the present figure operationalizesidentity as a parameterized chromatographic profile tied to releasespecifications for the HTF and its standardized solid compositions. Thisapproach addresses variability inherent to botanical materials by enforcing afingerprint-match criterion at release.

[0087] Accordingly, FIG. 1 provides the visual and analytical basis forlot qualification of the HTF, enabling the skilled person to confirm identity,detect process-induced drift, and ensure that only chromatographicallyconforming material progresses to formulation and final product testing, inalignment with the “Supporting Documents” enumerated in the application.

[0088] The HPLC chromatogram is interpreted in conjunction with thevalidated calibration curve for a representative marker, thereby linking identity(RT window; peak purity) to quantitation (linearity; % w / w result) for release

[0089] FIG. 2. Illustrates the HPLC chromatogram of the hydrolysable10tannin–rich fraction showing the retention-time window for ellagic acidemployed for routine identification and assay, according to an embodiment ofthe present invention.

[0090] Accordingly, FIG. 2 presents the high-performance liquidchromatography (HPLC) chromatogram of the hydrolysable-tannin–richfraction (HTF) obtained from Terminalia chebula, with specific annotation ofthe retention-time (RT) window for ellagic acid employed for routine identityconfirmation and quantitative assay of a representative marker compound. Thechromatographic record forms part of the “Supporting Documents” packagealongside the ellagic-acid calibration curve and the HR-LCMS base-peakchromatogram.

[0091] In embodiments, the HPLC method utilizes a reversed-phasecolumn operated under a defined gradient with UV / visible detection at awavelength suitable for polyphenolic chromophores, thereby resolving ellagicacid from co-eluting congeners present in the HTF matrix. The annotated RTwindow establishes the acceptable elution interval for the ellagic-acid peakrelative to a qualified reference standard, enabling lot-release confirmation ofidentity by RT match within predetermined tolerances.

[0092] The figure is interpreted in conjunction with the calibration curveof ellagic acid generated by the same HPLC method, which demonstratesresponse linearity across the quantitation range used for HTF assay. Together,the qualitative RT match (identity) and the quantitative calibration (assay)provide orthogonal evidence supporting both the presence and the controlledlevel of the marker in HTF batches proposed for standardized solid-formmanufacture.

[0093] According to preferred specifications, a batch conforms toidentity when the sample ellagic-acid peak exhibits an RT within ±ΔRTminutes of the reference standard run under system-suitability conditions, andwhen the peak displays a purity index above a defined threshold based onspectral consistency or diode-array analysis. System suitability includes,without limitation, resolution between ellagic acid and its nearest elutingimpurity, maximum allowable %RSD for replicate injections, and plate countcriteria prior to sample analysis.

[0094] The figure further supports assay acceptance criteria by indicatingthe integration boundaries and baseline strategy used to quantify ellagic acidin the presence of related substances. Assay results are reported as %w / w ofHTF with limits aligned to the pre-set marker-range specification disclosed forthe composition. Where applicable, correction factors and standard-purityadjustments are documented to ensure traceable quantitation.

[0095] In embodiments, the chromatogram is used to verify that relatedsubstancelevels near the ellagic-acid RT do not exceed defined qualificationthresholds and that no unresolved shoulders or co-elutions compromise thequantitation. Batches exhibiting split peaks, unacceptable tailing factors, or RTdrift beyond tolerance are rejected or investigated prior to advancement tostandardized solid-form processing.

[0096] The chromatographic identity furnished by FIG. 2 complementsthe HR-LCMS base-peak chromatogram (BPC) by providing a routine, UVbasedmethod suitable for quality control laboratories, while the BPC offershigh-resolution mass confirmation of the broader marker distribution. Thisdual-method approach (HPLC-UV for routine release; HR-LCMS forfingerprinting) reduces false qualifications and binds botanical origin tomeasurable analytical attributes.

[0097] In stability and technology-transfer contexts, the HPLCchromatogram serves as a reference record: the RT window, peak shape, andrelative response are compared over time and across laboratories to confirmmethod robustness. Any time-dependent changes in retention or emergentimpurities are trended against predefined action limits, with supportive HRLCMSchecks performed if drift is suspected.

[0098] The figure thereby operationalizes a lot-qualification workflow inwhich: (i) identity is established by RT match within tolerance; (ii) assay isderived from the validated calibration curve; and (iii) related-substancesurveillance is conducted within the same run. This integrated use of thechromatogram ensures that only HTF meeting marker content and puritytargets proceeds to blending, compression / encapsulation, and coating steps ofthe standardized solid compositions.

[0099] Accordingly, FIG. 2 provides the visual and analytical foundationfor routine QC of the HTF, enabling the skilled person to confirm presence andlevel of ellagic acid within a controlled RT window, verify absence ofinterfering co-elutions, and document compliance with specification limitsprior to release and downstream formulation, as set forth in the SupportingDocuments of the application.

[00100] FIG. 3. Illustrates relative gene-expression bar plots for AR,TMPRSS2, and SRD5A2 in testes, ventral prostate, and seminal vesicledemonstrating composition-linked modulation, according to an embodiment ofthe present invention.

[00101] Accordingly, FIG. 3 presents bar plots of relative gene expressionfor Androgen Receptor (AR), Transmembrane Serine Protease 2 (TMPRSS2),and Steroid 5α-Reductase Type 2 (SRD5A2) measured in three androgenresponsivetissues—testes, ventral prostate, and seminal vesicle—in animalsadministered the disclosed hydrolysable-tannin–rich fraction (HTF) versusrespective controls, according to an embodiment of the present invention. Theplots summarize mean fold-change with standard error of the mean (SEM) andsignificance annotations, thereby evidencing composition-linked modulationof androgen-axis genes.

[00102] In the testes, the figure indicates statistically significantdownregulation of all three targets: AR decreased by an average of −1.605-fold (Welch’s t-test, t(4)=5.468, p=0.0054), TMPRSS2 by −2.132-fold(t(4)=2.976, p=0.0409), and SRD5A2 by −5.268-fold (t(4)=13.23, p=0.0002),relative to control. These values are presented as negative fold-changes per theplotting convention described in the figure legend.

[00103] In the ventral prostate, the figure shows AR down to −2.147-fold(Welch’s t-test, t(7)=3.643, p=0.0083), TMPRSS2 to −2.045-fold (t(6)=3.613,p=0.0112), and SRD5A2 to −1.901-fold (t(7)=7.497, p=0.0001), each relativeto control. The concordant directionality across markers is consistent with acoherent modulation of androgen-responsive signaling in this tissue. In theseminal vesicle, AR expression decreased by −1.579-fold (Welch’s t-test,t(7)=4.603, p=0.0025), TMPRSS2 by −2.276-fold (t(7)=18.06, p<0.0001), andSRD5A2 by −2.545-fold (t(7)=7.374, p=0.0002), again reaching statisticalsignificance versus control. The magnitude and consistency of these reductionsacross three independent tissues reinforce the tissue-general nature of theobserved modulation.

[00104] As depicted in the legend, fold-changes are computed using aΔΔCT method with normalization to β-actin, and plotted as −1 / [2^−(ΔΔCT)]with −1 denoting no fold change; p-values are calculated using 2^−(ΔΔCT)values. The plots display mean with SEM and adopt standard significancethresholds (* p<0.05, ** p<0.01, *** p<0.001, **** p<0.0001), providing avalidated statistical framework for inter-group comparisons.

[00105] The collective downregulation of AR, TMPRSS2, and SRD5A2aligns with the invention’s premise that a composition-defined HTF—releasedto specification based on analytical markers—can produce reproducible genelevelmodulation in androgen-responsive tissues without reliance on systemichormonal suppression; elsewhere in the record, serum testosterone was notsignificantly altered under the tested conditions, supporting a non-depletivemechanism consistent with local pathway modulation.

[00106] The figure therefore functions as a mechanistic readout coupledto composition identity: only batches meeting the HTF’s marker-boundspecifications and chromatographic fingerprint are advanced to in-vivoevaluation, and the observed gene-expression pattern provides orthogonalconfirmation that the standardized composition maintains its intendedbiological profile across tissues.

[00107] From a quality and reproducibility perspective, the three-markerpanel across three tissues affords sensitivity to compositional drift: loss orattenuation of the characteristic downregulation signature would promptinvestigation into upstream parameters or analytical non-conformance, therebyintegrating the figure’s outputs into the lot-qualification and release-for-useframework disclosed elsewhere in the application.

[00108] The data presentation in FIG. 3 is thus configured to serve bothas: (i) evidentiary support for the technical effect associated with the HTF’sanalytically defined identity; and (ii) a decision aid within the control strategyfor standardized solid compositions, ensuring that only lots exhibiting theexpected fold-change pattern proceed to downstream formulation and stabilityprograms. Accordingly, FIG. 3 demonstrates composition-linked, statisticallyrobust downregulation of AR, TMPRSS2, and SRD5A2 in testes, ventralprostate, and seminal vesicle, thereby substantiating the invention’smechanistic narrative while remaining anchored to the HTF’s marker10constrained identity and associated release specifications.

[00109] FIG. 4. Illustrates representative liver and kidney histologicalmicrographs (100× / 200×) evidencing preserved tissue architecture in treatedanimals and supporting tolerability of the standardized compositions,according to an embodiment of the present invention.

[00110] Accordingly, FIG. 4 presents representative histologicalmicrographs of liver and kidney from animals administered the hydrolysabletannin–rich fraction (HTF), captured at approximately 100× and 200×magnification, according to an embodiment of the present invention. Thefigure is configured to evidence preserved hepatic and renal architecture intreated animals, thereby supporting the tolerability of the standardizedcompositions disclosed herein.

[00111] In the hepatic panels, the micrographs depict intact lobularorganization with central venules and radiating hepatic cords separated bysinusoidal channels. Hepatocyte plates are continuous and uniform, with nucleiexhibiting typical size and chromatin distribution, and without observableballooning, hydropic change, or necrotic foci. The portal triads present withinthe fields retain normal relationships among portal vein branches, hepaticartery branches, and bile ductules.

[00112] The renal panels demonstrate preserved cortical and medullarymorphology, including intact glomerular tufts with appropriate capillary loopdefinition and Bowman's space, and tubulointerstitial regions without tubulardilation, epithelial sloughing, or cast formation. No interstitial inflammatoryinfiltrates, hemorrhagic changes, or vascular congestion are apparent at thesurveyed magnifications, consistent with non-adverse histological status.

[00113] The combined liver and kidney histology is read in the context oforgan-weight observations taken at necropsy. While statistically significantdecreases were recorded in liver and kidney weights in the HTF cohort, theabsence of structural pathology in the corresponding histology providesevidence that the weight differences reflect physiological modulation ratherthan toxic injury, aligning with literature reports on hydrolysable tannins andlipid handling.

[00114] Specifically, the figure corroborates textual findings that “thehistology of both liver and kidneys revealed normal hepatic and renalarchitecture,” which rules out overt hepatotoxicity or nephrotoxicity at theinvestigated dose and dosing period. This conclusion is consistent acrossindependent descriptions within the record and supports advancement of HTFmaterial meeting release specifications into standardized solid-formdevelopment.

[00115] From a quality perspective, FIG. 4 functions as a safetyanchoringdataset complementary to analytical identity controls (e.g.,chromatographic fingerprints). The preserved parenchymal architecture acrosshepatic lobules and renal cortical / medullary regions indicates that batchessatisfying the HTF’s marker-bound specifications and processed into unitsolids under disclosed controls do not elicit structural organ damage under thetest conditions.

[00116] The documented magnification levels (approximately 100× and200×) provide sufficient resolution to detect common toxicopathic changes(e.g., steatosis, centrilobular necrosis, tubular degeneration) that wouldcontraindicate progression of a batch. The absence of such findings in thepresented micrographs reinforces the safety profile inferred from hematologyand serum chemistry panels reported elsewhere in the specification.

[00117] Accordingly, FIG. 4 substantiates that the standardizedcompositions comprising HTF—when qualified by the disclosed analyticalspecifications and manufactured within the stated control strategy—arecompatible with preserved hepatic and renal histology in vivo, therebyunderpinning the tolerability claims of the invention and distinguishing thedisclosed compositions from variably defined botanical extracts that lack suchhistological confirmation.

[00118] FIG. 5. Illustrates the calibration curve of ellagic acid generatedby HPLC analysis for quantitative assay validation of a marker compoundwithin the fraction, according to an embodiment of the present invention.

[00119] Accordingly, FIG. 5 presents the calibration curve of ellagic acidgenerated by a validated high-performance liquid chromatography (HPLC)method, according to an embodiment of the present invention. The curveestablishes the quantitative relationship between analyte concentration anddetector response for a representative marker compound within thehydrolysable-tannin–rich fraction (HTF), thereby enabling routine assay of lotsintended for standardized solid compositions.

[00120] In embodiments, the calibration curve is constructed from a seriesof ellagic-acid reference solutions spanning the method’s working range, eachprepared from a qualified primary standard with documented purity andweighed using a calibrated analytical balance. Dilutions are performed withsuitable class-A volumetrics to minimize volumetric error, and standard puritycorrections are applied where applicable to ensure traceable concentrationassignment.

[00121] The chromatographic method employs a reversed-phase columnoperated under a defined gradient program with UV / visible detection at awavelength selected for polyphenolic chromophores. Injection sequencetypically comprises solvent blank(s), ascending-concentration standards, mid10range reinjection(s) for drift assessment, and system-suitability checks,followed by sample analyses. Retention-time (RT) consistency and peak-shapeattributes for ellagic acid are verified prior to calibration acceptance.

[00122] The calibration function is evaluated using least-squares linearregression of peak area (or height) versus nominal concentration. Acceptancecriteria include, without limitation: (i) coefficient of determination not lessthan a predefined threshold; (ii) back-calculated concentrations for individualstandards within predefined percentage deviation of nominal; and (iii) yinterceptmagnitude within method-specified bounds. If non-linearity isdetected, appropriate weighting (e.g., 1 / x or 1 / x²) may be applied subject todocumented justification.

[00123] System suitability is demonstrated prior to and during calibrationby meeting criteria for baseline noise, signal-to-noise ratio at the lower limit ofquantitation, theoretical plates, tailing factor, and resolution from adjacent orpotential interfering peaks. Failure of any system-suitability parametermandates corrective action and repetition of the calibration sequence beforesample results are considered valid.

[00124] The figure annotates the accepted regression line together withrepresentative data points, and may include inset statistics (slope, intercept,coefficient of determination, and standard error), thereby documenting methodfitness for quantitative use. Where relevant, the dynamic range is labeled withthe lower and upper limits of quantitation, each supported by precision andaccuracy experiments conducted at those levels.

[00125] In embodiments, carryover assessment is performed bybracketing the highest-concentration standard with blanks and confirming thatany apparent response in the blank does not exceed the predefined acceptancelimit. Robustness to minor method variations (e.g., ± temperature, ± organiccontent, ± flow rate) is verified separately and does not materially alter thecalibration slope within allowable tolerance, ensuring reliable transfer acrossinstruments and sites.

[00126] The accepted calibration curve is applied to quantify ellagic acidin HTF samples by interpolating sample peak responses within the establishedrange, using the validated integration parameters shown or referenced in thefigure. Sample results are reported as %w / w of the fraction (or mg / g), aftercorrecting for dilution factors, sample moisture (if applicable), and standardpurity, thereby linking measured content to the marker-range specificationdisclosed for identity control.

[00127] From a quality-control perspective, FIG. 5 functions as afoundational record that ties routine assay results to a traceable, statisticallysupported calibration model. When used in concert with the HR-LCMSfingerprint and the HPLC RT-identity confirmation, the calibration curveenables lot release decisions that are anchored to both presence and controlledlevel of a key marker, reducing the risk of false qualification due to instrumentdrift or matrix interference.

[00128] Accordingly, FIG. 5 evidences that the quantitative assay ofellagic acid—implemented via a validated HPLC method with an acceptedcalibration curve—provides precise, accurate, and reproducible measurementof a representative marker within the HTF. This supports the invention’scontrol strategy by ensuring that only lots conforming to marker contentspecifications advance to standardized solid-form manufacture and stabilityprograms.G) ADVANTAGES OF THE INVENTION

[00129] An advantage of the present invention resides in the provision ofa defined hydrolysable-tannin–rich fraction (HTF) whose identity is anchoredto marker-based analytical specifications and chromatographic fingerprints,thereby overcoming variability associated with generic botanical “extracts.”

[00130] An advantage of the invention is the lot-to-lot reproducibilityachieved by constraining both absolute marker ranges and ratio-basedrelationships among markers, enabling enforceable identity boundaries ratherthan taxonomic labeling alone.

[00131] An advantage of the invention is the orthogonal identityframework employing HR-LCMS base-peak chromatograms for fingerprintconfirmation together with HPLC retention-time and calibrated assay forroutine QC, reducing the probability of false qualification due to single-methodlimitations.

[00132] An advantage of the invention is the standardized solid-formarchitecture (unit solids with specified excipient systems and optionalprotective / enteric coatings) configured to preserve hydrolysable tanninintegrity, thereby mitigating hydrolysis, oxidation, and moisture-drivendegradation.

[00133] An advantage of the invention is the defined dissolution profilelinked to coating parameters and excipient selection, enabling predictablerelease behavior across manufacturing lots and storage intervals.

[00134] An advantage of the invention is the content-uniformity controlestablished through particle-size governance, blending strategies, andgranulation constraints, ensuring that individual units meet predeterminedassay limits.

[00135] An advantage of the invention is the stability assurance achievedby coupling packaging barrier specifications and desiccant systems withacceptance criteria for marker retention, related substances, moisture, anddissolution over time.

[00136] An advantage of the invention is the process–specificationlinkage that detects compositional drift arising from upstream parameterexcursions (e.g., extraction pH / time, partition order, resin-elution conditions)via predefined chromatographic and ratio tolerances.

[00137] An advantage of the invention is the scalability and transferabilityof the control strategy, wherein critical quality attributes (CQAs) and criticalprocess parameters (CPPs) are mapped to proven acceptable ranges,facilitating technology transfer without loss of identity or performance.

[00138] An advantage of the invention is the analytical traceabilityprovided by validated calibration curves for representative markers, system25suitability criteria, and reference standards, thereby enabling auditable,statistics-backed quantitation.

[00139] An advantage of the invention is the reduction of batch failuresthrough integrated in-process controls (blend uniformity, LOD limits,compression and coating windows) that constrain thermal and moistureexposures known to affect polyphenolic stability.

[00140] An advantage of the invention is the compatibility with qualityby-design (QbD) principles, allowing risk-based control strategies andcontinuous verification of identity and performance from raw fraction tofinished unit solids.

[00141] An advantage of the invention is the safety-anchoring dataset(e.g., preserved hepatic and renal histology under test conditions; hematologyand serum-chemistry consistency), which, when coupled with identityconformity, supports tolerability of standardized compositions.

[00142] An advantage of the invention is the mechanism-aligned readouts(e.g., composition-linked modulation of AR, TMPRSS2, SRD5A2 expressionin androgen-responsive tissues in laboratory rats) that serve as orthogonalfunctional confirmations of the standardized composition’s biological profilewithout reliance on systemic endocrine suppression.

[00143] An advantage of the invention is the reduced reliance on broadtraditional-knowledge disclosures by defining a specific fraction of commerce(composition of matter) through measurable analytical attributes, therebyaddressing objections associated with loosely defined herbal materials.

[00144] An advantage of the invention is the manufacturing robustnessarising from predefined environmental controls (temperature, relativehumidity), residence-time limits, and packaging WVTR specifications, whichcollectively dampen environmental sensitivity of hydrolysable tannins.

[00145] An advantage of the invention is the documentation and kitability(e.g., CoA with marker ranges and ratios; method references; storageguidance), enabling consistent downstream handling and verification acrosssites and throughout distribution.

[00146] An advantage of the invention is the regulatory readiness affordedby explicit identity, assay, impurities, dissolution, and stability specifications,facilitating specification-driven release and lifecycle management ofstandardized solid compositions.

[00147] Collectively, the foregoing advantages provide a compositioncentric,specification-bound solution that converts a variable botanical sourceinto a reproducible fraction and standardized solid form with controlledidentity, stability, and performance, thereby distinguishing the invention fromvariably characterized plant extracts lacking enforceable quality attributes.

Claims

1. A standardized solid composition titled “HYDROLYSABLE-TANNIN-RICH FRACTION FROM TERMINALIA CHEBULA AND STANDARDIZED SOLID COMPOSITIONS”, the composition comprising: (i) a hydrolysable-tannin-rich fraction (HTF) obtained from Terminalia chebula, the HTF being a human-made composition of commerce analytically defined by: (a) a total hydrolysable tannin content of 85% to 98% w / w of the dry fraction; (b) a marker panel comprising chebulagic-type and chebulinic-type ellagitannins and gallotannins including chebulagic acid, chebulinic acid, corilagin, and tellimagrandin I, each present within a respective quantitative range; (c) free ellagic acid at 1.0% to 5.0% w / w; and (d) an analytical fingerprint selected from HPLC and HR-LCMS criteria comprising retention-time windows for said markers within preset tolerances and a base-peak chromatogram in negative ionization mode exhibiting a marker-distribution pattern and ion-ratio profile within preset limits; and (ii) one or more ingestible excipients selected from diluents, binders, disintegrants, glidants, lubricants, and coating polymers; wherein the composition is provided as unit solid forms that meet content-uniformity and dissolution release specifications defined for the HTF.

2. The composition of claim 1, wherein chebulagic acid is 5% to 20% w / w, chebulinic acid is 10% to 30% w / w, corilagin is 1% to 10% w / w, and tellimagrandin I is 10% to 40% w / w, each value determined by a validated chromatographic method.

3. The composition of claim 1 or 2, wherein the HTF satisfies at least one ratio constraint selected from chebulagic acid:chebulinic acid, (chebulagic 10 acid+corilagin):tellimagrandin I, and chebulinic acid:corilagin, each ratio falling within a predetermined interval recorded for batch release.

4. The composition of any one of claims 1-3, wherein residual solvents each comply with ICH-aligned limits and moisture of the HTF is < 5% w / w by Karl Fischer titration.

5. The composition of any one of claims 1-4, wherein HPLC identity is confirmed when each marker peak elutes within ±ART minutes of a qualified reference and exhibits a peak-purity index above a preset threshold, and HR-LCMS identity is confirmed when accurate-mass ions for the marker panel are within ±5 ppm of theoretical with ion-ratio tolerances satisfied.

6. The composition of any one of claims 1-5, wherein the unit solid form is selected from tablet, mini-tablet, capsule, pellet, or granule, and comprises an optional protective or enteric coating configured to limit acid-phase release and enable post-gastric release.

7. The composition of any one of claims 1-6, wherein the dissolution specification comprises: (a) at pH 1.2, not more than 10% of quantified HTF markers released at 120 minutes; and (b) at pH 6.8, not less than 80% of the same markers released within 45 minutes following exposure to the higher-pH medium.

8. The composition of any one of claims 1-7, wherein the coating polymer is selected from methacrylic acid copolymers, cellulose derivatives, or polyvinyl polymers with a film weight gain of 1% to 8%, and the plasticizer is selected from triacetin, citrate esters, or polyethylene glycols.

9. The composition of any one of claims 1-8, wherein the excipient system maintains water activity < 0.40 within the unit solid form at 25 °C / 60% RH.

10. The composition of any one of claims 1-9, wherein content uniformity of a marker selected from chebulagic acid or ellagic acid satisfies acceptance value (AV) < 15 under compendial testing.

11. The composition of any one of claims 1-10, wherein related substances attributable to hydrolysis or oxidation of hydrolysable tannins each do not exceed preset qualification thresholds and total related substances do not exceed a preset total limit at release and at labeled shelf life.

12. The composition of any one of claims 1-11, further comprising a packaging system selected from barrier blisters, HDPE bottles, or foil-laminate sachets incorporating a desiccant, the primary package exhibiting a water-vapour transmission rate not exceeding a preset limit sufficient to maintain moisture and dissolution within specification for shelf life.

13. The composition of claim 12, wherein the secondary packaging includes documentation comprising a certificate of analysis listing marker ranges, ratio constraints, HPLC / HR-LCMS identity results, dissolution criteria, and storage instructions.

14. The composition of any one of claims 1-13, wherein in-process controls comprise blend uniformity, loss-on-drying limits, and coating process windows including inlet air temperature, product temperature, atomization air pressure, and spray rate, each maintained within proven acceptable ranges to preserve HTF identity.

15. The composition of any one of claims 1-14, wherein batch release requires concurrent conformance to: (i) HPLC retention-time identity as recited in claim 5; (ii) HR-LCMS fingerprint criteria as recited in claim 5; and (iii) the dissolution specification of claim 7.

16. The composition of any one of claims 1-15, wherein storage at 25 °C / 60% RH for 6 months or 40 °C / 75% RH for 3 months maintains marker contents, ratio constraints, related-substance limits, and the dissolution profile within specification.